Search

Collaboration with the EMA on Joint Clinical Assessments and Joint Scientific Consultations under the HTA Regulation

The European Hematology Association (EHA) welcomes the draft Implementing Act laying down procedural rules for the exchange of information between the Health Technology Assessment (HTA) Coordination Group, the European Commission, and the European Medicines Agency (EMA).

Read more

EHA returns to Cairo with the Highlights of the 24th EHA Congress

The 4th Highlights of Past EHA (HOPE) Middle East & North Africa (MENA) took place (for the third time) in Cairo, Egypt, organized in collaboration with the Pan Arab Hematology Association (PAHA) and hosted by the Egyptian Society of Hematology…

Read more

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more

Learn more on the EHA Campus

EHA has developed EHA Campus courses related to previous EHA-LSHBT Virtual Hematology Updates. The aim of the courses is to add to your learning experience, making the information discussed during the webinars available in an interactive and engaging way.

Read more

EHA-SWG on AAA a virtual meeting with a worldwide approach covering all aspects of the disease!

Live days: April 29-30, 2021

Content available: April 22, 2021 – May 29, 2021

Chair: Prof Dr C Dufour

Junior and senior hematologists from all over the world gathered on April 29-30, 2021 for the live days of the EHA-SWG Scientific Meeting on…

Read more

Acute Lymphocytic Leukemia: impressive results with the monoclonal antibody blinatumomab

The Phase 2 dose-ranging study MT103-206 evaluated the efficacy, safety and tolerability of blinatumomab in adult patients with B-precursor Acute Lymphoblastic Leukemia who had relapsed following treatment with standard front-line chemotherapy or allogeneic stem cell transplant.

Read more

Revising the ICH Guidelines on Clinical Trials

The EHA delegation to the ICH meeting: from left to right, Professors Christian Gisselbrecht, Steven Le Gouill and Martin Dreyling. Clinical trials and drug development have become more complex over the years.

Read more

EHA Statement on the Erasmus MC Attack

EHA is deeply saddened and appalled by the news of the twin shootings in Rotterdam, the Netherlands. We condemn these senseless acts of violence in the strongest possible terms.

Read more

EHA Statement: Our sustained solidarity with the hematology community in Ukraine

Friday, February 24 marks one year of war. The European Hematology Association (EHA) stands in solidarity with our colleagues and friends in Ukraine.

Read more